A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction
Latest Information Update: 07 Sep 2023
At a glance
- Drugs GW 406381 (Primary) ; Naproxen sodium
- Indications Dental pain; Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors GSK
- 01 Sep 2009 Results were published in the Clinical Journal of Pain.
- 16 Oct 2006 Status change
- 18 Nov 2005 New trial record.